List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 National Number Alessia HEXAL 0,06 mg/ 0,015 mg Filmtabletten /H/0424/ HEXAL AG DE Arianna 60 microgrammi / 15 microgrammi compresse rivestite con film /H/0159/ BAYER SPA IT Arianna 60 microgrammi / 15 microgrammi compresse rivestite con film /H/0159/ BAYER SPA IT Arianna 60 microgrammi / 15 microgrammi compresse rivestite con film /H/0159/ BAYER SPA IT Etinilestradiol + Gestodeno Stallpharma 0,02 mg + 0,075 mg Comprimidos revestidos not available Etinilestradiol + Gestodeno Stallpharma 0,02 mg + 0,075 mg Comprimidos revestidos not available Etinilestradiol + Gestodeno Stallpharma 0,02 mg + 0,075 mg Comprimidos revestidos not available STALLPHARMA, PRODUTOS FARMACÊUTICOS LDA. STALLPHARMA, PRODUTOS FARMACÊUTICOS LDA. STALLPHARMA, PRODUTOS FARMACÊUTICOS LDA. PT Fedra 0,075 mg + 0,02 mg compresse rivestite not available BAYER SPA IT FEMODEN not available 56/220/93-C BAYER PHARMA AG CZ Femoden 0,03 mg/0,075 mg obložene tablete not available 5363-I-2183/12 BAYER PHARMA AG SI Femoden 0,03mg/0,075 mg obalené tablety not available 17/140/94-S BAYER PHARMA AG SK Femoden 75/30 mikrogrammi kaetud tabletid not available BAYER PHARMA AG EE Femoden 75/30 mikrogramu apvalkotās tabletes not available BAYER PHARMA AG LV PT PT EMA/719205/2016 Page 2/14

3 National Number Femoden 75/30 mikrogramų dengtos tabletės not available LT/1/96/2476/001 BAYER PHARMA AG LT Femoden bevont tabletta not available OGYI-T-2360/02 BAYER PHARMA AG HU Femoden bevont tabletta not available OGYI-T-2360/01 BAYER PHARMA AG HU Femoden dragerade tabletter not available 9970 BAYER OY FI Femoden päällystetyt tabletit not available 9970 BAYER OY FI Femoden, 0,075 mg + 0,03 mg, tabletki powlekane not available R/0601 BAYER PHARMA AG PL Femodene not available PL 00010/0529 BAYER PLC UK Femodene 0,075 / 0,030 mg, comprimés enrobés not available BE BAYER SA NV BE Femodene 0,075 / 0,030 mg, comprimés enrobés not available BAYER SA NV LU Femodene 0,075 / 0,030 mg, omhulde tabletten not available BE BAYER SA NV BE Femodene 0,075 / 0,030 mg, überzogene Tabletten not available BE BAYER SA NV BE Femodene 0,075 / 0,030 mg, überzogene Tabletten not available BAYER SA NV LU FEMODENE ED not available PL 00010/0530 BAYER PLC UK Femodette not available PL 00010/0531 BAYER PLC UK Femovan 0,03mg / 0,075mg überzogene Tabletten not available JENAPHARM GMBH & CO KG DE Gestoden/Etinilestradiol Sandoz 75 micrograme/30 micrograme comprimate NL/H/3352/ /2016/01 S.C. SANDOZ S.R.L. RO Gestoden/Etinilestradiol Sandoz 75 micrograme/30 micrograme comprimate NL/H/3352/ /2016/02 S.C. SANDOZ S.R.L. RO Gestoden/Etinilestradiol NL/H/3352/ /2016/03 S.C. SANDOZ S.R.L. RO EMA/719205/2016 Page 3/14

4 National Number Sandoz 75 micrograme/30 micrograme comprimate GINODEN 0,075 mg + 0,03 mg compresse rivestite not available BAYER SPA IT Gynera, 0,03 mg + 0,075 mg, comprimido revestido not available BAYER PORTUGAL LDA PT Gynera, 0,03 mg + 0,075 mg, comprimido revestido not available BAYER PORTUGAL LDA PT Gynovin - Dragees not available BAYER AUSTRIA GMBH AT Gynovin 0,075 mg / 0,03 mg comprimidos recubiertos not available BAYER HISPANIA SL ES Harmonet not available (IS) PFIZER APS IS Harmonet 0,02 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT Harmonet 0,02 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT Harmonet 0,02 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT Harmonet 0,02 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT HARMONET 0,075 mg + 0,02 mg compresse rivestite not available PFIZER ITALIA S.R.L. IT Harmonet 0,075 mg/0,020 mg comprimés enrobés not available BE PFIZER S.A. (BELGIUM) BE Harmonet 0,075 mg/0,020 mg drajeuri (gestoden/etinilestradiol) not available 3697/2011/04 PFIZER EUROPE MA EEIG RO Harmonet 0,075 mg/0,020 mg drajeuri (gestoden/etinilestradiol) not available 3697/2011/03 PFIZER EUROPE MA EEIG RO Harmonet 0,075 mg/0,020 mg drajeuri (gestoden/etinilestradiol) not available 3697/2011/01 PFIZER EUROPE MA EEIG RO EMA/719205/2016 Page 4/14

5 National Number Harmonet 0,075 mg/0,020 mg drajeuri (gestoden/etinilestradiol) not available 3697/2011/02 PFIZER EUROPE MA EEIG RO Harmonet 0,075 mg/0,020 mg omhulde tabletten not available BE PFIZER S.A. (BELGIUM) BE Harmonet 0,075 mg/0,020 mg Überzogene Tabletten not available BE PFIZER S.A. (BELGIUM) BE Harmonet 75 mikrogramai / 20 mikrogramų dengtos tabletės not available LT/1/98/0362/002 PFIZER EUROPE MA EEIG LT Harmonet 75 mikrogramai / 20 mikrogramų dengtos tabletės not available LT/1/98/0362/001 PFIZER EUROPE MA EEIG LT Harmonet 75 mikrogrami/20 mikrogrami apvalkotās tabletes not available PFIZER EUROPE MA EEIG LV Harmonet 75 mikrogramm/20 mikrogramm bevont tabletta not available OGYI-T-6969/01 PFIZER KFT. HU Harmonet 75 mikrogramm/20 mikrogramm bevont tabletta not available OGYI-T-6969/02 PFIZER KFT. HU Harmonet 75 mikrogramov/20 mikrogramov obložene tablete not available 5363-I-718/13 PFIZER EUROPE MA EEIG SI HARMONET 75/20 microgramos comprimidos recubiertos not available WYETH FARMA, S.A ES Harmonet 75/20 mikrogrammi kaetud tabletid not available PFIZER EUROPE MA EEIG EE Harmonet tablett, dragerad not available PFIZER OY FI EMA/719205/2016 Page 5/14

6 National Number Harmonet tabletti, päällystetty not available PFIZER OY FI HARMONET obalené tablety not available 17/058/99 C PFIZER, SPOL. S R.O. CZ Harmonet, 75 mikrogramów (μg) + 20 mikrogramów (μg), tabletki drażowane not available 4871 PFIZER EUROPE MA EEIG PL HARMONET, comprimé enrobé not available HARMONET, comprimé enrobé not available Harmonet, overtrukne tabletter not available PFIZER APS DK Harmonette Dragees 75 Mikrogramm/ 20 Mikrogramm überzogene Tabletten not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. AT Kosidina 0,075 mg/0,030 mg 21+7, tabletten NL/H/3352/002 RVG SANDOZ B.V. NL Lenisagyn - 1 A Pharma /H/0425/ A PHARMA GMBH DE Logest not available 17/530/96-C BAYER PHARMA AG CZ LOGEST 0,02 mg / 0,075 mg obložene tablete not available UP/I /12-02/369 BAYER DOO HR Logest 0,02 mg/0,075 mg obalené tablety not available 17/0179/98-S BAYER PHARMA AG SK Logest 0,02 mg/0,075 mg obložene tablete not available H/00/00937/001 BAYER PHARMA AG SI Logest 0,075 mg/0,02 mg, drajeuri not available 6335/2014/01 BAYER PHARMA AG RO Logest 75 mikrogramai / 20 mikrogramų dengtos tabletės not available LT/1/97/2779/001 BAYER PHARMA AG LT Logest 75 mikrogramu/20 mikrogramu apvalkotās not available BAYER PHARMA AG LV EMA/719205/2016 Page 6/14

7 National Number tabletes Logest, 0,075 mg + 0,02 mg, tabletki powlekane not available 4189 BAYER PHARMA AG PL Logest, 75/20 mikrogrammi kaetud tabletid not available BAYER PHARMA AG EE Lunafem not available 17/215/07-C BAYER PHARMA AG CZ Meliane - Dragees not available BAYER AUSTRIA GMBH AT Meliane 0,020 mg/0,075 mg bevont tabletta not available OGYI-T-6814/01 BAYER PHARMA AG HU Meliane 0,020 mg/0,075 mg bevont tabletta not available OGYI-T-6814/02 BAYER PHARMA AG HU Meliane 0,075 / 0,020 mg, comprimés enrobés not available BE BAYER SA NV BE Meliane 0,075 / 0,020 mg, comprimés enrobés not available BAYER SA NV LU Meliane 0,075 / 0,020 mg, omhulde tabletten not available BE BAYER SA NV BE Meliane 0,075 / 0,020 mg, überzogene Tabletten not available BE BAYER SA NV BE Meliane 0,075 / 0,020 mg, überzogene Tabletten not available BAYER SA NV LU Meliane 0,075 mg / 0,02 mg comprimidos recubiertos not available BAYER HISPANIA SL ES Meliane Diario 0,075 mg/0,02 mg comprimidos recubiertos not available BAYER HISPANIA SL ES Meliane dragerade tabletter not available BAYER OY FI Meliane päällystetty tabletit not available BAYER OY FI MELIANE, comprimé enrobénot available BAYER HEALTHCARE MELIANE, comprimé enrobénot available BAYER HEALTHCARE MELODENE-15 0,06 mg/ 0,015 mg comprimidos /H/159/ BAYER HISPANIA SL ES EMA/719205/2016 Page 7/14

8 National Number recubiertos con película MELODIA 60 microgrammes / 15 microgrammes, comprimé pelliculé /H/159/ BAYER HEALTHCARE MELODIA 60 microgrammes / 15 microgrammes, comprimé pelliculé /H/159/ BAYER HEALTHCARE MICROGESTE 60 microgramas/15 microgramas comprimido revestido por película /H/0159/ BAYER PORTUGAL LDA PT MICROGESTE 60 microgramas/15 microgramas comprimido revestido por película /H/0159/ BAYER PORTUGAL LDA PT Milvane compresse rivestite not available BAYER SPA IT Milvane, 0,05 mg + 0,03 mg; 0,07 mg + 0,04 mg; 0,10 mg + 0,03 mg, tabletki powlekane not available 4340 BAYER PHARMA AG PL MINESSE 0,06 mg/0,015 mg comprimidos recubiertos con película /H/0158/ WYETH FARMA, S.A ES MINESSE 15 Mikrogramm/60 Mikrogramm Filmtabletten /H/0158/ PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. AT microgramas/15 microgramas comprimido revestido por película /H/0158/ LABORATÓRIOS PFIZER, LDA. PT microgramas/15 microgramas comprimido /H/0158/ LABORATÓRIOS PFIZER, LDA. PT EMA/719205/2016 Page 8/14

9 National Number revestido por película microgramas/15 microgramas comprimido revestido por película /H/0158/ LABORATÓRIOS PFIZER, LDA. PT microgrammes/15 microgrammes, comprimé pelliculé /H/0158/ microgrammes/15 microgrammes, comprimé pelliculé /H/0158/ microgrammi/15 microgrammi compresse rivestite con film /H/0158/ PFIZER ITALIA S.R.L. IT microgrammi/15 microgrammi compresse rivestite con film /H/0158/ PFIZER ITALIA S.R.L. IT microgrammi/15 microgrammi compresse rivestite con film /H/0158/ PFIZER ITALIA S.R.L. IT micrograms / 15 micrograms film-coated tablet /H/0158/001 PA 0822/144/001 PFIZER HEALTHCARE IRELAND IE micrograms / 15 micrograms film-coated tablet not available MA505/06301 PFIZER HELLAS, A.E. MT MINESSE potahované tablety not available 17/123/00-C PFIZER, SPOL. S R.O. CZ Minigeste, 0,02 mg + 0,075 mg, comprimido not available BAYER PORTUGAL LDA PT EMA/719205/2016 Page 9/14

10 National Number revestido Minigeste, 0,02 mg + 0,075 mg, comprimido revestido not available BAYER PORTUGAL LDA PT Minulet - Dragees 75 Mikrogramm/ 30 Mikrogramm überzogene Tabletten not available PFIZER CORPORATION AUSTRIA GESELLSCHAFT M.B.H. AT Minulet 0,03 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT Minulet 0,03 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT Minulet 0,03 mg + 0,075 mg comprimido revestido not available LABORATÓRIOS PFIZER, LDA. PT MINULET 0,075 mg + 0,03mg compresse rivestite not available PFIZER ITALIA S.R.L. IT Minulet 0,075 mg/0,030 mg comprimés enrobés not available BE PFIZER S.A. (BELGIUM) BE Minulet 0,075 mg/0,030 mg omhulde tabletten not available BE PFIZER S.A. (BELGIUM) BE Minulet 0,075 mg/0,030 mg Überzogene Tabletten not available BE PFIZER S.A. (BELGIUM) BE Minulet 75 micrograms/30 micrograms Coated Tablets not available PA 0822/093/001 PFIZER HEALTHCARE IRELAND IE Minulet 75 mikrogramm/30 mikrogramm bevont tabletta not available OGYI-T-2382/02 PFIZER KFT. HU Minulet 75 mikrogramov/30 mikrogramov obložene tablete not available 5363-I-471/12 PFIZER EUROPE MA EEIG SI MINULET 75/30 microgramos comprimidos recubiertos not available WYETH FARMA, S.A ES MINULET obalené tablety not available 17/200/89 C PFIZER, SPOL. S R.O. CZ Minulet tablett, dragerad not available 9971 PFIZER OY FI EMA/719205/2016 Page 10/14

11 National Number Minulet tabletti, päällystetty not available 9971 PFIZER OY FI MINULET, comprimé enrobé not available MINULET, comprimé enrobé not available Minulet, dragees not available RVG PFIZER B.V. NL Minulet, overtrukne tabletter not available PFIZER APS DK Mirelle 0,06 mg/0,015 mg filmom obalené tablety not available 17/0322/00-S BAYER PHARMA AG SK Mirelle 15 Mikrogramm/60 Mikrogramm Filmtabletten /H/159/ BAYER AUSTRIA GMBH AT Mirelle 60 / 15 mikrogramų plėvele dengtos tabletės not available LT/1/01/2826/001 BAYER PHARMA AG LT Mirelle 60 microgram / 15 microgram, filmomhulde tablet /H/159/01 BE BAYER SA NV BE Mirelle 60 microgrammes / 15 microgrammes, comprimé pelliculé /H/159/01 BE BAYER SA NV BE Mirelle 60 microgrammes / 15 microgrammes, comprimé pelliculé /H/159/ BAYER SA NV LU MIRELLE 60 mikrogram/15 mikrogram, filmdragerade tabletter /H/159/ BAYER OY FI Mirelle 60 Mikrogramm/15 Mikrogramm, Filmtabletten /H/159/01 BE BAYER SA NV BE Mirelle 60 Mikrogramm/15 Mikrogramm, Filmtabletten /H/159/ BAYER SA NV LU Mirelle 60/15 mikrogrammi õhukese polümeerikattega tabletid not available BAYER PHARMA AG EE EMA/719205/2016 Page 11/14

12 National Number Mirelle 60/15 mikrogramu apvalkotās tabletes not available BAYER PHARMA AG LV Mirelle 60 mikrog / 15 mikrog, kalvopäällysteiset tabletit /H/159/ BAYER OY FI MONEVA, comprimé enrobé not available BAYER HEALTHCARE MONEVA, comprimé enrobé not available BAYER HEALTHCARE OPTINESSE 75 microgrammes/20 microgrammes, comprimé enrobé not available NL LABORATOIRES MAJORELLE OPTINESSE 75 microgrammes/30 microgrammes, comprimé enrobé not available NL LABORATOIRES MAJORELLE PHAEVA, comprimé enrobé not available BAYER HEALTHCARE PHAEVA, comprimé enrobé not available BAYER HEALTHCARE SYLVIANE, comprimé pelliculé not available BAYER HEALTHCARE SYLVIANE, comprimé pelliculé not available BAYER HEALTHCARE TRI MINULET, comprimé enrobé not available TRI MINULET, comprimé enrobé not available TRI MINULET, comprimé enrobé not available TRI MINULET, comprimé enrobé not available TRIADENE not available PL 00010/0563 BAYER PLC UK Tri-Femoden dragerade tabletter not available BAYER OY FI Tri-FemodenÒ päällystetyt tabletit not available BAYER OY FI EMA/719205/2016 Page 12/14

13 National Number Tri-Gynera, (0,03 mg + 0,05 mg) + (0,04 mg + 0,07 mg) + (0,03 mg + 0,10 mg), comprimidos revestidos not available BAYER PORTUGAL LDA PT Tri-Gynera, (0,03 mg + 0,05 mg) + (0,04 mg + 0,07 mg) + (0,03 mg + 0,10 mg), comprimidos revestidos not available BAYER PORTUGAL LDA PT Trigynovin comprimidos recubiertos not available BAYER HISPANIA SL ES Tri-Minulet (0,03 mg + 0,05 mg) + (0,04 mg + 0,07 mg) + (0,03 mg + 0,1 mg) comprimidos revestidos not available LABORATÓRIOS PFIZER, LDA. PT Tri-Minulet (0,03 mg + 0,05 mg) + (0,04 mg + 0,07 mg) + (0,03 mg + 0,1 mg) comprimidos revestidos not available LABORATÓRIOS PFIZER, LDA. PT Tri-Minulet Coated* Tablets not available PA 822/099/001 PFIZER HEALTHCARE IRELAND IE TRIMINULET compresse rivestite not available PFIZER ITALIA S.R.L. IT Tri-Minulet comprimés enrobés not available BE PFIZER S.A. (BELGIUM) BE TRI-MINULET comprimidos recubiertos not available WYETH FARMA, S.A ES Tri-Minulet omhulde tabletten not available BE PFIZER S.A. (BELGIUM) BE Tri-Minulet Überzogene Tabletten not available BE PFIZER S.A. (BELGIUM) BE Triodena - Dragees not available BAYER AUSTRIA GMBH AT Triodena bevont tabletta not available OGYI-T-5465/02 BAYER PHARMA AG HU EMA/719205/2016 Page 13/14

14 National Number Triodena bevont tabletta not available OGYI-T-5465/01 BAYER PHARMA AG HU Triodene, comprimés enrobés not available BE BAYER SA NV BE Triodene, comprimés enrobés not available 0442/ BAYER SA NV LU Triodene, omhulde tabletten not available BE BAYER SA NV BE Triodene, überzogene Tabletten not available BE BAYER SA NV BE Triodene, überzogene Tabletten not available 0442/ BAYER SA NV LU Yaluvea 0,06 mg / 0,015 mg Filmtabletten NL/H/1901/ HORMOSAN PHARMA GMBH DE Логест 0,02 mg/0,075 mg обвити таблетки not available BAYER PHARMA AG BG Фемоден 0,03 mg/0,075 mg обвити таблетки not available BAYER PHARMA AG BG EMA/719205/2016 Page 14/14

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Mylan 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 24 January 2018 EMA/270645/2015 Human Medicines Evaluation Division Active substance: azithromycin (systemic use formulations) Procedure no.: PSUSA/00010491/201704 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT BIJSLUITER: INFORMATIE VOOR DE PATIËNT Sitagliptine Teva 25 mg, filmomhulde tabletten Sitagliptine Teva 50 mg, filmomhulde tabletten Sitagliptine Teva 100 mg, filmomhulde tabletten Sitagliptin Read all

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metfmin HCl Aurobindo 500 mg/ 850 mg/ 1000 mg, film-coated tablets metfmin hydrochlide Read all of this leaflet carefully befe you start taking this medicine.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride PACKAGE LEAFLET: INFORMATION FOR THE USER Metformin HCl Bluefish 500 mg/ 850 mg/ 1000 mg, film-coated tablets metformin hydrochloride Read all of this leaflet carefully before you start taking this medicine

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride

Package leaflet: Information for the patient. Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Package leaflet: Information for the patient Levocetirizine Krka 5 mg film-coated tablets Levocetirizine dihydrochloride Read all of this leaflet carefully before you start taking this medicine because

More information

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use

(Invented) Name. Crestor 5 mg Filmtabletten. Filmtabletten. Filmtabletten. Filmtabletten. Crestor 5 mg Film coated tablets Oral use Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, route of and marketing authorisation holders in the Member s 1 Austria Austria Austria Austria Belgium Belgium Belgium

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Etoricoxib

PACKAGE LEAFLET: INFORMATION FOR THE USER. Etoricoxib PACKAGE LEAFLET: INFORMATION FOR THE USER ARCOXIA 30 mg film-coated tablets ARCOXIA 60 mg film-coated tablets ARCOXIA 90 mg film-coated tablets ARCOXIA 120 mg film-coated tablets Etoricoxib Read all of

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

Annex I. List of nationally authorised medicinal products and marketing authorisation applications

Annex I. List of nationally authorised medicinal products and marketing authorisation applications Annex I List of nationally authorised medicinal products and marketing authorisation applications 1 Annex IA: Medicinal products recommended for maintenance and marketing authorisation applications for

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Kalcipos-D forte 500 mg/800 IU film-coated tablets. Calcium/cholecalciferol (Vitamin D3)

Package leaflet: Information for the user. Kalcipos-D forte 500 mg/800 IU film-coated tablets. Calcium/cholecalciferol (Vitamin D3) Package leaflet: Information for the user Kalcipos-D forte 500 mg/800 IU film-coated tablets Calcium/cholecalciferol (Vitamin D3) Read all of this leaflet carefully before you start using this medicine

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Sevelamer Carbonate Rowex 800mg Film-coated tablets sevelamer carbonate Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel

Package leaflet: Information for the user. Clopidogrel 75 mg film-coated tablets. Clopidogrel Package leaflet: Information for the user Clopidogrel 75 mg film-coated tablets Clopidogrel Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Aurobindo 5 mg film-coated tablets Simvastatin Aurobindo 10 mg film-coated tablets Simvastatin Aurobindo 20 mg film-coated tablets Simvastatin Aurobindo

More information

Please note that this draft Annex I will be updated to amend information on concerned products/mahs

Please note that this draft Annex I will be updated to amend information on concerned products/mahs 22 March 2018 EMA/197481/2018 Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of, applicants, marketing authorisation holders in the member states for for omega-3

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib

PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib PACKAGE LEAFLET: INFORMATION FOR THE USER Arcoxia 60 mg Film coated Tablets Arcoxia 90 mg Film coated Tablets etoricoxib Read all of this leaflet carefully before you start taking this medicine. Keep this

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 November 2017 EMA/845743/2017 Human Medicines Evaluation Division Active substance: ibuprofen, ibuprofen lysine (not indicated in ductus arteriosus) Procedure no.: PSUSA/00010345/201702 30 Churchill

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

Package leaflet: information for the user. Levonorgestrel/Ethinylestradiol Chemical Farma 150/30 microgram, filmomhulde tabletten

Package leaflet: information for the user. Levonorgestrel/Ethinylestradiol Chemical Farma 150/30 microgram, filmomhulde tabletten Package leaflet: information for the user Levonorgestrel/Ethinylestradiol Chemical Farma 150/30 microgram, filmomhulde tabletten Levonorgestrel / Ethinylestradiol Read all of this leaflet carefully before

More information

Package leaflet: Information for the patient. Optinate Septimum 35 mg film-coated tablets risedronate sodium

Package leaflet: Information for the patient. Optinate Septimum 35 mg film-coated tablets risedronate sodium Package leaflet: Information for the patient Optinate Septimum 35 mg film-coated tablets risedronate sodium Read all of this leaflet carefully before you start taking this medicine because it contains

More information

BIJSLUITER: INFORMATIE VOOR DE PATIËNT

BIJSLUITER: INFORMATIE VOOR DE PATIËNT PACKAGE LEAFLET 1 BIJSLUITER: INFORMATIE VOOR DE PATIËNT Cinacalcet 30 mg Teva, filmomhulde tabletten Cinacalcet 60 mg Teva, filmomhulde tabletten Cinacalcet 90 mg Teva, filmomhulde tabletten Cinacalcet

More information

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil

Package leaflet: Information for the user. Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Package leaflet: Information for the user Tadalafil teva 10 mg film-coated tablet Tadalafil teva 20 mg film-coated tablet tadalafil Read all of this leaflet carefully before you start taking this medicine

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Bluefish 10 mg film-coated tablets Simvastatin Bluefish 20 mg film-coated tablets Simvastatin Bluefish 40 mg film-coated tablets Simvastatin Bluefish

More information

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette

Marketing Authorisation Holder Invented name Strength Pharmaceutical Form. Postinor 1500 Mikrogramm-Tablette Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of, marketing authorisation holders in the Member States 1 Levonorgestrel-containing emergency contraceptive medicinal

More information

Package leaflet: Information for the user. Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets calcium/cholecalciferol (vitamin D 3 )

Package leaflet: Information for the user. Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets calcium/cholecalciferol (vitamin D 3 ) Package leaflet: Information for the user Calciflex-D 3 Citron 500 mg/400 IU film-coated tablets calcium/cholecalciferol (vitamin D 3 ) For medicinal products available only on prescription: Read all of

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER 60 mg Film coated Tablets 90 mg Film coated Tablets 120 mg Film coated Tablets (etoricoxib) (etoricoxib) (etoricoxib) Read all of the leaflet carefully before

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

PACKAGE LEAFLET. Package leaflet: Information for the patient

PACKAGE LEAFLET. Package leaflet: Information for the patient PACKAGE LEAFLET Package leaflet: Information for the patient Etoricoxib 30 mg Film-coated tablets Etoricoxib 60 mg Film-coated tablets Etoricoxib 90 mg Film-coated tablets Etoricoxib120 mg Film-coated

More information

1. What Bisoprolol Fumarate tablet is and what it is used for

1. What Bisoprolol Fumarate tablet is and what it is used for Package leaflet: Information for the user Bisoprolol 2.5 mg film-coated tablets Bisoprolol 5 mg film-coated tablets Bisoprolol 10 mg film-coated tablets Bisoprolol fumarate Read all of this leaflet carefully

More information

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY

EUROPEAN CITIZENS DIGITAL HEALTH LITERACY Flash Eurobarometer 404 EUROPEAN CITIZENS DIGITAL HEALTH LITERACY SUMMARY Fieldwork: September 2014 Publication: November 2014 This survey has been requested by the European Commission, Directorate-General

More information

Package leaflet: Information for the user. Montelukast 10 mg film-coated tablets. Montelukast

Package leaflet: Information for the user. Montelukast 10 mg film-coated tablets. Montelukast Package leaflet: Information for the user Montelukast 10 mg film-coated tablets Montelukast Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten

Sortis 10 mg - Filmtabletten. Sortis 20 mg - Filmtabletten. Sortis 40 mg - Filmtabletten. Sortis 80 mg - Filmtabletten Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States 1 Member State EU/EEA Austria Austria

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

Package Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil

Package Leaflet: Information for the user. Tadalafil 10 mg film-coated tablets Tadalafil Package Leaflet: Information for the user Tadalafil 10 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Valtan 80mg Film-coated Tablets

Valtan 80mg Film-coated Tablets Package leaflet: Information for the user Valtan 80mg Film-coated Tablets Valsartan Read all of this leaflet carefully before you start taking this medicine because it contains important information for

More information

Package leaflet: Information for the user. Capecitabine Sandoz 150 mg Film-coated tablets Capecitabine Sandoz 500 mg Film-coated tablets.

Package leaflet: Information for the user. Capecitabine Sandoz 150 mg Film-coated tablets Capecitabine Sandoz 500 mg Film-coated tablets. Package leaflet: Information for the user 150 mg Film-coated tablets 500 mg Film-coated tablets capecitabine Read all of this leaflet carefully before you start taking this medicine because it contains

More information

Package leaflet: Information for the user Sildenafil Aurobindo 50 mg film-coated tablets Sildenafil Aurobindo 100 mg film-coated tablets Sildenafil

Package leaflet: Information for the user Sildenafil Aurobindo 50 mg film-coated tablets Sildenafil Aurobindo 100 mg film-coated tablets Sildenafil Package leaflet: Information for the user Sildenafil Aurobindo 50 mg film-coated tablets Sildenafil Aurobindo 100 mg film-coated tablets Sildenafil Read all of this leaflet carefully before you start taking

More information

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin

Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin PACKAGE LEAFLET: INFORMATION FOR THE USER Simvastatin Teva 10 mg Film-coated Tablets Simvastatin Teva 20 mg Film-coated Tablets Simvastatin Teva 40 mg Film-coated Tablets Simvastatin Read all of this leaflet

More information

Package leaflet: Information for the patient

Package leaflet: Information for the patient Package leaflet: Information for the patient Atorvastatin 10 mg Film-coated Tablets Atorvastatin 20 mg Film-coated Tablets Atorvastatin 40 mg Film-coated Tablets Atorvastatin 80 mg Film-coated Tablets

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

Package Leaflet: Information for the user. Tadalafil 20 mg film-coated tablets Tadalafil

Package Leaflet: Information for the user. Tadalafil 20 mg film-coated tablets Tadalafil Package Leaflet: Information for the user Tadalafil 20 mg film-coated tablets Tadalafil Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten

(Invented) Name Strength Pharmaceutical form. Ergotop 10 mg - Tabletten. Ergotop 20 mg - Filmtabletten. Ergotop 30 mg - Filmtabletten Annex I List of the names, pharmaceutical (s), strength(s) of the medicinal product(s), route(s) of, marketing authorisation holder(s) in the member states 1 Bulgaria Bulgaria Czech Republic Kwizda Pharma

More information

Palliative nursing care of children and young people across Europe

Palliative nursing care of children and young people across Europe Palliative nursing care of children and young people across Europe Results of a postal survey in August 2016 Updated in April 2017 (presented at the 29th PNAE-meeting in Naples/Italy on 28th April 2017)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)

More information

Transmission, processing and publication of HBS 2015 data

Transmission, processing and publication of HBS 2015 data EUROPEAN COMMISSION EUROSTAT Directorate F: Social statistics Unit F-4: Income and living conditions; Quality of life Doc. LC-ILC/194/17/EN estat.f.4 (2017) WORKING GROUP ON INCOME AND LIVING CONDITIONS

More information